Univar Solutions' Ingredients + Specialties division has been appointed as the distributor for Ingredion Pharma Solutions, creating an exclusive distribution channel for pharmaceutical starches within the United States and Canada.

Elisabeth Gardiner, PhD, CSO of Tevard Biosciences, explains some of the challenges associated with the development of treatments for rare diseases.

Trust-based CDMO partnerships are becoming essential to accelerate injectable drug development, manage risk, and ensure resilient biopharma supply.

Innovators are increasingly focused on whether outsourced partners can help them make better decisions earlier, before uncertainty becomes late-stage risk.

In response to Marty Makary warning the US may lose the early‑stage drug development lead to China, Brian Scanlan says speed, AI‑driven CDMOs, and focused specialization are now critical.

Industry experts discuss the benefits of utilizing contract development and contract research organizations in drug discovery and development.

Using patent intelligence data from the FounderNest platform, Gonzalez highlights where small-molecule synthesis, formulation, and manufacturing innovation is accelerating, and what it means for pharma competition this year.

FDA's Plausible Mechanism Framework streamlines individualized therapy approvals for ultra-rare diseases.

It is necessary to search beyond the term “data integrity” to stay abreast of developments in this field, says Siegfried Schmitt, PhD, vice president, Technical at Parexel.

PharmTech spoke with Andrew Mitchell, associate vice president of Business Development at BioVectra, about which 2025 trends will continue to impact the pharma industry and how CDMOs can offer solutions.

This week, we highlight big news from Roche, BMS, GSK, J&J, and Lilly, as well as well as key insights from industry experts.

SCOTUS struck down IEEPA tariffs. Pharma duties under Section 232 persist as they fall outside the ruling's scope.

FDA commissioner warns US trial startup delays may cede early drug development to China, urging IND and IRB process reforms amid global competitions.

A $1 Billion Pennsylvania cell therapy site investment bolsters domestic manufacturing, creating 500 skilled biomanufacturing jobs.

In this episode of Ask the Expert, Susan J. Schniepp, Nelson Labs, and Siegfried Schmitt, Parexel, discuss the benefits of orphan drug development and how a mid-sized company can work with regulators through the pathway to approval.

Eli Lilly & CSL seal a deal for clazakizumab partitions rights to maximize lifecycle value. CSL retains ESKD focus as Lilly prioritizes commercialization.

In part three of this four-part series regarding rare diseases, the authors examine how revenue concentration and accelerating patent cliffs undermine the traditional blockbuster model, whereas orphan drugs offer a structurally different strategy for stabilizing biopharma portfolios through more durable, predictable, and risk-adjusted long-term value creation.

The European approval for GSK's depemokimab joins recently announced data on vaccine efficacy and progress on 4-month viral treatments.

FDA has accepted the NDA for BMS's Iberdomide, an oral agent targetting relapsed/refractory multiple myeloma.

Gazyva phase III MAJESTY study met its primary endpoint, showing superior complete remission in primary membranous nephropathy.

This week, we highlight AI efficiency, modular hardware, onshoring, Alzheimer's DMTs, and the impact of women in STEM leadership.

EMA recommends withdrawing levamisole from the EU market due to serious leukoencephalopathy risks that outweigh clinical benefits.

JIN-A02 is a fourth-gen EGFR inhibitor targeting EGFR C797S resistance in lung cancer, showing brain activity and tumor regression.

Suzanne Jansen, MSc, PharmD, ICON, says early-phase clinical success depends on flexible, simple formulations that support wide dose ranges, matching placebos, and robust stability.

New disease-modifying agents are being evaluated in the clinic that could change the course of treatment for Alzheimer’s disease patients.

Fujifilm’s £400m (US $547m) Teesside expansion adds 19,000L single-use capacity and an innovation center to boost global biopharma development.

IMA Group acquired ProSys to expand its global aseptic and containment portfolio for biopharmaceutical manufacturing.

Dr. Jennifer Levin Carter, CEO and founder of Medzown, shares her experience as a CEO in the biotech industry and gives insights on how women can succeed in the pharmaceutical industry.